The Q4 result was announced after market hours on Wednesday, 29 May 2013.
Meanwhile, the S&P BSE Sensex was down 10.14 points or 0.05% at 20,137.50.
On BSE, 1.97 lakh shares were traded in the counter as against average daily volume of 1.17 lakh shares in the past one quarter.
The stock hit a high of Rs 403.40 and a low of Rs 391.55 so far during the day. The stock had hit a 52-week low of Rs 300.70 on 12 June 2012. The stock had hit a record high of Rs 435 on 9 January 2013.
The stock had underperformed the market over the past one month till 29 May 2013, declining 1.47% compared with the Sensex's 3.92% rise. The scrip had, however, outperformed the market in past one quarter, jumping 11.31% as against Sensex's 6.82% gain.
The large-cap company has equity capital of Rs 160.58 crore. Face value per share is Rs 2.
Cipla's revenue from India operations rose 5.2% to Rs 793 crore in Q4 March 2013 over Q4 March 2012. The growth in revenue from the domestic business was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments. Exports of formulations rose 11.5% to Rs 954 crore in Q4 March 2013 over Q4 March 2012. Exports of active pharmaceutical ingredients (APIs) fell 24% to Rs 175 crore in Q4 March 2013 over Q4 March 2012. The company attributed growth in overall export revenue to growth in anti-asthma, anti-allergic, anti-depressants, and anti-retroviral segments.
Cipla is one of India's leading pharmaceutical companies. With over 34 manufacturing units across the country, the company manufactures over 2,000 products in 65 therapies. It has a state of the art R&D centre.
Powered by Capital Market - Live News
